AsthmaPhase 4NCT00363480
Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data
A Phase 4 study testing Salmeterol/Fluticasone 50/250 mcg, Salbutamol 100 mcg and DISKUS™ powder inhalers in people with Asthma, run by GlaxoSmithKline at 32 sites in Germany.
Trial summary
The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Seretide (salmeterol/fluticasone combination, SFC)… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Asthma
- What is being tested?
- Salmeterol/Fluticasone 50/250 mcg, Salbutamol 100 mcg and DISKUS™ powder inhalers
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 221 participants
- Where
- 32 sitesGermany
- Study dates
- 17 May 2006to 14 Sep 2007
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of asthma
- Reversibility >12% after inhalation of 200 µg Salbutamol
- willingness and ability to complete daily record card on daily basis and to measure morning PEF on daily basis
- 80% compliance in diary card completion asthma control status: Uncontrolled based on the GOAL criteria
Who cannot join
- Change of asthma medication during the last 4 weeks
- Asthma exacerbation characterized by use of oral corticoids during the last 3 months Pretreatment with inhaled corticosteroids more than 500 mcg Beclometasondipropionat or equivalent per day or other controller therapy during the last 3 months
- upper or lower respiratory tract infection during the RUN-IN period moderate or severe asthma exacerbation during the RUN-IN period
- Non compliance with use of Discus, PEF-meter and incomplete diary card data
Trial locations and contacts
32 sites in 1 country.
32 sites in 1 country
Germany32 sites
GSK Investigational Site
Bad Arolsen, Hesse, 34454
GSK Investigational Site
Berlin, 10367
GSK Investigational Site
Berlin, 10717
GSK Investigational Site
Berlin, 10965
GSK Investigational Site
Berlin, 12165
GSK Investigational Site
Berlin, 12687
GSK Investigational Site
Berlin, 13187
GSK Investigational Site
Berlin, 13597
GSK Investigational Site
Braunschweig, Lower Saxony, 38100
GSK Investigational Site
Buchholz, Lower Saxony, 21244
GSK Investigational Site
Chemnitz, Saxony, 09126
GSK Investigational Site
Cottbus, Brandenburg, 03050
GSK Investigational Site
Dresden, Saxony, 01099
GSK Investigational Site
Erlangen, Bavaria, 91052
GSK Investigational Site
Eschwege, Hesse, 37269
GSK Investigational Site
Geesthacht, Schleswig-Holstein, 21502
GSK Investigational Site
Greiz, Thuringia, 07973
GSK Investigational Site
Hamburg, 22767
GSK Investigational Site
Hanover, Lower Saxony, 30159
GSK Investigational Site
Hanover, Lower Saxony, 30167
GSK Investigational Site
Kassel, Hesse, 34117
GSK Investigational Site
Kassel, Hesse, 34121
GSK Investigational Site
Kaufbeuren, Bavaria, 87600
GSK Investigational Site
Landsberg am Lech, Bavaria, 86899
GSK Investigational Site
Marburg, Hesse, 35037
GSK Investigational Site
Munich, Bavaria, 80335
GSK Investigational Site
Munich, Bavaria, 81677
GSK Investigational Site
Rednitzhembach, Bavaria, 91126
GSK Investigational Site
Sonneberg, Thuringia, 96515
GSK Investigational Site
Uttenreuth, Bavaria, 91080
GSK Investigational Site
Wedel, Free and Hanseatic City of Hamburg, 22880
GSK Investigational Site
Würzburg, Bavaria, 97070
About this study
Official title: Asthma Control Assessment Via ACT and DRC in Asthmatics Treated With Seretide (50/250) Over 12 Weeks
The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Seretide (salmeterol/fluticasone combination, SFC) 50/250 µg twice daily. The asthma control test (ACT) will be used to detect differences in the level of asthma control during treatment. The study aims to show a correlation between improvements of ACT und the level of asthma control which will be reached by the patients.
The aim of the study is to show that most of symptomatic asthma patients can reach 'well controlled asthma' with SFC. We get information about ACT in daily practice and physicians are trained to use the asthma control test as a screening tool and for follow up of asthma management. Correlations are expected between the improvements in ACT, Quality of Life and asthma control according to the Gaining Optimal Asthma controL (GOAL) criteria.
- Conditions
- Asthma
- Being tested
- Salmeterol/Fluticasone 50/250 mcg, Salbutamol 100 mcg, DISKUS™ powder inhalers
- Keywords
- Asthma, Asthma Control Test, SERETIDE
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Salmeterol/Fluticasone 50/250 mcgDrug
Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
Salbutamol 100 mcgDrug
This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
DISKUS™ powder inhalersDevice
Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
| Study group | Role | What they receive |
|---|---|---|
| SFC 50/250 mcg | Experimental | Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria. Receives: Drug: Salmeterol/Fluticasone 50/250 mcg; Drug: Salbutamol 100 mcg; Device: DISKUS™ powder inhalers |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12
A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score >1 (Range: 0= None to 5= severe), rescue salbutamol use on <= 2 days and at most 4 occasions per week, and a morning peak flow >= 80% of the predicted value on each day per week. All of the criteria which includes no night-time awakenings due to asthma (diary entry), no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change are fulfilled. The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control.
Measured: Week 9 to Week 12
Secondary outcomes (16)
Change From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12
The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. In order to derive the total ACT score, all 5 questions needed to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Measured: Baseline (Visit 3) and Week 12
Change From Baseline in Mean ACT Score at Visit 6
The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms not under control. In order to derive the total ACT score, all 5 questions had to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Measured: Baseline (Viait 3) and Week 12
Number of Participants With Well Controlled and Totally Controlled Asthma at Week 12
Well controlled or totally controlled asthma assessments were done according to the GOAL criteria. A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score >1(Range: 0= None to 5= severe), rescue salbutamol use on <= 2 days and at most 4 occasions per week, and morning peak flow >= 80% of the predicted value on each day per week. All of the criteria which included no night-time awakenings due to asthma (diary entry),no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change were fulfilled. The total ACT score was based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Measured: Week 12
Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)
For the level of asthma control, baseline values were derived taking the last 8 weeks during the pre-treatment period prior to Visit 3 into consideration. Regarding derived variables based on the asthma diary, data from the last week prior to Visit 3 was taken. Visit 3, regarded as baseline. AQLQ has 32 questions regarding activities, emotions, symptoms, and environmental triggers. Each item values range from 1 (maximum impairment) to 7 (no impairment). A positive change from baseline score indicates improvement.
Measured: Baseline (Visit 3) up to Week 12
Correlation of Change in AQLQ Score and Change in ACT Score
Correlation between change in the AQLQ and ACT score was tabulated using the Pearson coefficient of correlation (linear correlation). The AQLQ contained 32 items in 4 domains: activity limitation, symptoms, emotional function and environmental stimuli. Scores for the domains as well as the overall score were scaled within a range of 1 (worst) to 7 (best).
Measured: Week 12
Change From Baseline in Forced Expiratory Volume (FEV1) to Week 12
FEV1, an amount of air exhaled by a person during a forced breath in one second. FEV1 assessed at Visit 1 and at Visits 3, 4, 5, 6. Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.
Measured: Baseline (Visit 3) up to Week 12
Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12
PEF, a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. The mean morning PEF evaluated by means of the data documented in the asthma diaries. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Measured: Baseline (Visit 3) and Week 12
Change From Baseline in Mean 24-hour Symptom Score at Week 12
The various symptoms like wheezing, shortness of breath, coughing and chest tightness were assessed by the participants every morning using a symptom score scale which ranged from 0 (no symptoms during the past 24 hours) to 5 (symptoms so severe that participant could not go to work or carry out other normal daily activities). Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Measured: Baseline (Visit 3) and Week 12
Change From Baseline in Number of Additional Usage of Salbutamol at Week 12
Salbutamol was given as a rescue medicine, used on <= 2 days and at most 4 occasions per week. Change from baseline value was calculated by subtracting the baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.
Measured: Baseline (Visit 3) and week 12
Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12
Number of nights with no night time awakening were recorded at Week 12. Baseline was the last corresponding time period immediately prior to Visit 3.
Measured: Baseline (Visit 3) and week 12
Number of Participants With Emergency Visits Due to Asthma
Frequencies of emergency visits per participant were recorded during treatment period. Only the participants at risk were considered when calculating the incidence rates.
Measured: Up to week 12
Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment
AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with AE who lead to change in asthma treatment were reported.
Measured: Up to Week 12
Assessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE
An AE is any untoward medical occurrence in a participant or clinical AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with at least one treatment emergent serious and, non-serious AE were reported.
Measured: Up to Week 12
Assessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.
Measured: Baseline (Visit 3) up to Week 12
Assessment of Tolerability by Change From Baseline of Pulse Rate
Pulse rate was recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.
Measured: Baseline (Visit 3) up to Week 12
Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements
Frequencies of participants with at least one (near-) incident associated with peak flow measurements were recorded. analysis was done on safety population.
Measured: Up to Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Aug 2006 (estimated)
- Study start17 May 2006
- Primary completion1 Sep 2007
- Study completion14 Sep 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for AsthmaStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 221 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00363480
- Sponsor's protocol ID
- SAM 106538
- Status last verified
- Mar 2018
- First submitted
- 10 Aug 2006
- Last updated
- 9 Mar 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Asthma Control Assessment Via ACT and DRC in Asthmatics Treated With Seretide (50/250) Over 12 Weeks
- ClinicalTrials.gov ID
- NCT00363480
- Acronym / sponsor ID
- SAM 106538
- Conditions
- Asthma
- Keywords
- Asthma, Asthma Control Test, SERETIDE
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 221 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- 17 May 2006 (actual)
- Primary completion
- 1 Sep 2007 (actual)
- Study completion
- 14 Sep 2007 (actual)
- First posted
- 15 Aug 2006 (estimated)
- Results
- Posted 9 Mar 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Seretide (salmeterol/fluticasone combination, SFC) 50/250 µg twice daily. The asthma control test (ACT) will be used to detect differences in the level of asthma control during treatment. The study aims to show a correlation between improvements of ACT und the level of asthma control which will be reached by the patients.
The aim of the study is to show that most of symptomatic asthma patients can reach 'well controlled asthma' with SFC. We get information about ACT in daily practice and physicians are trained to use the asthma control test as a screening tool and for follow up of asthma management. Correlations are expected between the improvements in ACT, Quality of Life and asthma control according to the Gaining Optimal Asthma controL (GOAL) criteria.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SFC 50/250 mcg | Experimental | Drug: Salmeterol/Fluticasone 50/250 mcg, Drug: Salbutamol 100 mcg, Device: DISKUS™ powder inhalersParticipants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of asthma
- Reversibility >12% after inhalation of 200 µg Salbutamol
- willingness and ability to complete daily record card on daily basis and to measure morning PEF on daily basis
- 80% compliance in diary card completion asthma control status: Uncontrolled based on the GOAL criteria
Key exclusion criteria (4 listed)
- Change of asthma medication during the last 4 weeks
- Asthma exacerbation characterized by use of oral corticoids during the last 3 months Pretreatment with inhaled corticosteroids more than 500 mcg Beclometasondipropionat or equivalent per day or other controller therapy during the last 3 months
- upper or lower respiratory tract infection during the RUN-IN period moderate or severe asthma exacerbation during the RUN-IN period
- Non compliance with use of Discus, PEF-meter and incomplete diary card data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Salmeterol/Fluticasone 50/250 mcgParticipant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers. | Drug | SFC 50/250 mcg |
| Salbutamol 100 mcgThis medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. | Drug | SFC 50/250 mcg |
| DISKUS™ powder inhalersParticipant received salmeterol and fluticasone using DISKUS™ powder inhalers. | Device | SFC 50/250 mcg |
Primary outcome
Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12
Time frame: Week 9 to Week 12
A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score >1 (Range: 0= None to 5= severe), rescue salbutamol use on <= 2 days and at most 4 occasions per week, and a morning peak flow >= 80% of the predicted value on each day per week. All of the criteria which includes no night-time awakenings due to asthma (diary entry), no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change are fulfilled. The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control.
16 secondary outcomes
Change From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12
Time frame: Baseline (Visit 3) and Week 12
Change From Baseline in Mean ACT Score at Visit 6
Time frame: Baseline (Viait 3) and Week 12
Number of Participants With Well Controlled and Totally Controlled Asthma at Week 12
Time frame: Week 12
Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)
Time frame: Baseline (Visit 3) up to Week 12
Correlation of Change in AQLQ Score and Change in ACT Score
Time frame: Week 12
Change From Baseline in Forced Expiratory Volume (FEV1) to Week 12
Time frame: Baseline (Visit 3) up to Week 12
Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12
Time frame: Baseline (Visit 3) and Week 12
Change From Baseline in Mean 24-hour Symptom Score at Week 12
Time frame: Baseline (Visit 3) and Week 12
Change From Baseline in Number of Additional Usage of Salbutamol at Week 12
Time frame: Baseline (Visit 3) and week 12
Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12
Time frame: Baseline (Visit 3) and week 12
Number of Participants With Emergency Visits Due to Asthma
Time frame: Up to week 12
Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment
Time frame: Up to Week 12
Assessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE
Time frame: Up to Week 12
Assessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Time frame: Baseline (Visit 3) up to Week 12
Assessment of Tolerability by Change From Baseline of Pulse Rate
Time frame: Baseline (Visit 3) up to Week 12
Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements
Time frame: Up to Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
32 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Salmeterol/Fluticasone 50/250 mcg, Salbutamol 100 mcg and DISKUS™ powder inhalers in people with Asthma, run by GlaxoSmithKline at 32 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 32 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Mar 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12 (time frame: Week 9 to Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2018.